ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

esmo.org

ESMO Advanced Course on Metastatic EGFR Mutant NSCLC

Programme

SEOUL
KOREA

28-29 OCTOBER 2016

Co-Chairs
Rolf A. Stahel, Switzerland
Keunchil Park, South Korea

This ESMO Advanced Course aims to update and inform clinicians on the latest developments in the understanding of the development of resistance to TKI therapies, the genetic origins of the resistance and the latest diagnostic and clinical developments enabling the clinical management of resistance in NSCLC patients.

WELCOME MESSAGE

Our knowledge and understanding of cancer is growing rapidly.
Hence, it is only appropriate for ESMO to expand its educational offering and guarantee that oncology professionals worldwide are always up to date and equipped to provide the best care to cancer patients.

The ESMO Advanced Course on metastatic EGFR mutant NSCLC offers oncologists the opportunity to participate in a comprehensive course, exploring the issue of resistance to therapies as well as clinical benefits and challenges that new therapies offer, to oncologists and patients alike.

During this course you will be able to attend state-of-the-art lectures in an interactive setting, you will benefit from ample time to present your questions to the faculty and to participate in highly interactive workshops: the unique structure of the programme will enable each participant to take the most out of the sessions, making sure all relevant areas of the multidisciplinary approach to cancer care are fully assimilated.

We feel this new educational programme will benefit you as an oncology professional and that you will be able to translate this new knowledge into your daily practice for the benefit of your patients.

Dr. Rolf A. Stahel
Zurich, Switzerland
Course chair

Dr. Keunchil Park
Seoul, Korea
Local Course chair

GENERAL INFORMATION

DESCRIPTION

This ESMO advanced course aims to update and inform clinicians on the latest developments in the understanding of the development of resistance to TKI therapies, the genetic origins of the resistance and the latest diagnostic and clinical developments enabling the clinical management of resistance in NSCLC patients.
Advanced courses provide state of the art lectures in an interactive setting made possible by providing ample time for delegates to present questions to the course faculty members and through the inclusion in the programme of highly interactive workshops.

LEARNING OBJECTIVES

- To understand the biology and role of EGFR and TKI's (1st, 2nd, 3rd generation) in the management of NSCLC
- To understand the development of resistance to TKI's and the available treatment options
- To understand the role of T790M in the development of resistance
- To understand the utility of different diagnostic methods in identifying the resistance mechanism
- To understand the importance of the multidisciplinary team and particularly the pathologist and radiologists in optimising diagnosis and selection of the most appropriate treatment options

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org

CONFERENCE RESOURCES

The conference webcast will include all session of the official programme where speaker permission is granted. The webcast will be available on the ESMO website at esmo.org.

CERTIFICATE OF ATTENDANCE

All participants will receive a certificate of attendance upon completion of the *Evaluation form*.

VENUE

Conrad Hotel Seoul
10 Gukjegeumyung-ro (Yeouido) Yeongdeungpo-gu
Seoul, 07326; South Korea

INSURANCE

The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.

ACKNOWLEDGEMENTS

AstraZeneca has provided a sponsorship grant towards this independent Programme.

AstraZeneca

EDUCATIONAL PROGRAMME

Friday, 28 October 2016

13:00-13:10 Welcome and Introduction: Keunchil Park, KR and Rolf A. Stahel, CH

13:00-15:40 Session 1 – The already long journey of EGFR TKI

Targeting oncogenetic drivers in NSCLC
Rolf A. Stahel, Switzerland

1st line treatment of EGFR m+: benefit from 1st generation TKI vs. Chemo
Tony Mok, Hong Kong

Contribution of 2nd generation TKI in 1st or 2nd line
Sanjay Popat, United Kingdom

Mechanisms of 1st generation resistance
Byoung Chul Cho, South Korea

Treatment of EGFR resistant patients with T790M as resistance mechanisms
Myung-Ju Ahn, South Korea

15:40-16:10 Coffee Break

16:10-18:55 Session 2 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions

Biopsy - key to the diagnostics initially and at progression
Erik Thunnissen, Netherlands

Diagnostic with alternative sample types (liquid biopsy)
James Chih-Hsin Yang, Taiwan

Associations between diagnostics and clinical outcomes (incl. patient handling algorithm)
Ji-Youn Han, South Korea

Progression after third generation TKI – what next?
Yuichiro Ohe, Japan

Strategy to improve outcome in EGFR mutant NSCLC
Ross Soo, Singapore

ESMO Guidelines in advanced NSCLC in 2016
Rolf A. Stahel, Switzerland

19:00 Dinner

EDUCATIONAL PROGRAMME

Saturday, 29 October 2016

8:30-12:15 Session 3 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions

Practical aspects with the examples of multiple patient cases; 4 parallel sessions (45' each including 15' introduction based on cases by speakers followed by discussion). 15' break between each; 50 delegates in each group

Breakout Workshop sessions

45' NSCLC patient with CNS involvement, *Chao-Hua Chiu, Taiwan*
15' Break
45' How to successfully engage radiologist to the NSCLC Patient Team? *Dae Hee Han, South Korea*
15' Break
45' How to successfully engage pathologist to the NSCLC Patient Team? *Tony Lim Kiat Hon, Singapore*
15' Break
45' How to define progression and treatment modification? *Se-Hoon Lee, South Korea*

12:15-13:00 Report back by group leaders to all delegates

13:00-13:15 Conclusion and wrap-up: Keunchil Park, KR and Rolf A. Stahel, CH

13:15-14:15 Lunch

COURSE OFFICERS

Rolf A. Stahel
Zurich, Switzerland

Rolf A. Stahel, was a founding member and the first President of the Swiss Society for Medical Oncology. He served as President of the Swiss Institute for Applied Cancer Research from 1999 to 2005.
He is a member of the International Association for the Study of Lung Cancer (IASLC), where he served as Chair of the Fellowship Committee and as member of the Board of Directors 2009-2013. In the European Society for Medical Oncology (ESMO) he served as National Representative for Switzerland from 1998-2004, he chaired the ESMO Task Force on Guidelines from 1999-2005 and the ESMO Educational Committee 2006-2011. Since 2003 he is a member of the ESMO Executive Board, serving as President-elect 2012-2013, President 2014-2015 and Past-President and Chair of the Membership Committee 2016-2017.

Since 2008 he is President of the Foundation Council of the International Breast Cancer Study Group (IBCSG). Since 2009 he is President of the European Thoracic Oncology Platform (ETOP), a foundation with the aim to bring together European collaborative groups and institutions focusing on research on thoracic malignancies.

He is Editor in-Chief of *Lung Cancer* and Editor of *Cancer Treatment Reviews and Progress in Tumour Research*.

Keunchil Park
Seoul, South Korea

Professor Park has served as Chair of the Scientific Committee of the Korean Cancer Association and Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG). Member of the Korean Association for Clinical Oncology (KACO) from June 2010 to May 2012, where he served as Chairman of the Board of Directors. Actively involved in international activities such as Scientific Secretary for the 12th World Conference on Lung Cancer (WCLC; Sept, 2007), and as President of the 4th Asia Pacific Lung Cancer Conference (Dec, 2010). *He served the IASLC as the Board of Directors 2009 - 2013*.

Associate Editor for the Journal of Thoracic Oncology (JTO), Prof. Park has recently joined the International Cancer Genome Consortium (ICGC) with the Korean Lung Cancer Genome Projects and is a member of the ICGC International Scientific Steering Committee since 2013. In 2017 he is going to host the ICGC workshop in Seoul and also the 2017 WCLC as Co-President with Prof. Hisao Asamura, Japan. He is the organizing Chairman of the 13th ICGC workshop to be held next June 13-15, 2017 in Seoul, Korea. Prof. Park has recently initiated the Korea Actionable Genome Consortium (KAGC) under the auspices of the Korea Cancer Association.

Prof. Park's main interests include experimental & translational researches as well as early clinical trials for the upper aero-digestive tract cancers, especially lung cancer. Dr. Park is leading several early clinical trials of the targeted agents as well as many pre-clinical development programs internationally. Prof. Park has authored several book chapters and more than 300 peer-reviewed publications in national and international journals.

COURSE OFFICERS

Tony Mok
Hong Kong

Prof. Tony S. K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is the Past President of the International Association for the Study of Lung Cancer (IASLC), Past Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People's Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Editor on Thoracic Oncology for Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.

Sanjay Popat
London, United Kingdom

Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.
Sanjay qualified from Guy's and St Thomas' Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.
He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.
He Chairs the British Thoracic Oncology Group (BTOG), and is Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).

COURSE OFFICERS

Byoung Chul Cho
Seoul, South Korea

Dr Cho is currently Associate Professor at the Division of Medical Oncology, Yonsei Cancer Center in Seoul, South Korea. Dr Cho is a director of Yuhan-Yonsei Lung Cancer Clinical and Translational Medicine Center. Dr Cho has spoken at many regional conferences, and sat on various regional advisory boards. Progressing rapidly in research experience, Dr Cho has published more than 100 papers in international peer-reviewed journals, such as Lancet Oncology, Journal of Clinical Oncology and Clinical Cancer Research, of which a significant number are on thoracic malignancies. He is currently an associate editor of the Lung Cancer.

His main research interest lies in molecular mechanisms of acquired resistance to targeted therapies and biomarker discovery in thoracic and head and neck cancer. Dr Cho has conducted many clinical trials with novel targeted agents in lung, head and neck cancer and esophageal squamous cell carcinoma and has led many nationwide, multicenter trials of targeted therapy in thoracic malignancies.

Myung-Ju Ahn
Seoul, South Korea

Myung-Ju Ahn is Professor of Hemato-Oncology in the Department of Medicine at Sungkyunkwan University School of Medicine in Seoul, Korea. She is a member of numerous associations and societies dedicated to cancer research, such as the International Society of Lung Cancer Association, the American Association of Cancer Research, and the Korean Cancer Study Group, where she is also Chief of the executive committee. She serves as a board member for the Korean Association of Cancer and the Korean Association of Clinical Oncology.

Professor Ahn received her education from Hanyang University College of Medicine in Seoul, where she earned her medical degree, as well as her doctorate. She completed her residency training in internal medicine at Hanyang University Hospital, and held numerous fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center in New York, USA.

As an active member of the cancer research community, Professor Ahn has authored over 215 publications. Her research interests include the development of predictive and prognostic marker in lung cancer in terms of personalized therapy, and her recent research focuses on the establishment of the xenograft model from patients' tumors for the development of drug discovery and reposition of targeted drugs, as well as the development of non-small cell lung cancer genome atlas. In recognition of her dedication to cancer research, she has been awarded multiple honors, including the 2003 Best Researcher Award from the Korean Medical Women's Association.

COURSE OFFICERS

Erik Thunnissen
Amsterdam, Netherlands

Erik Thunnissen is consultant pathologist and staff member at the Department of Pathology, VUmc in Amsterdam, with main interest in Pulmonary Pathology.

He is a long standing member of IASLC (International Association Study of Lung Cancer) pathology committee leading reproducibility studies of the WHO classification for lung cancer.

Furthermore, he has taken responsibility for pulmonary molecular external quality assessment (EQA) programs in the Netherlands and for the European Society of Pathology and UKNEQAS.

James Chih-Hsin Yang
Taipei, Taiwan

Dr James Chih-Hsin Yang is currently the Director and Professor of Graduate Institute of Oncology at National Taiwan University. He is also the director at Department of Oncology at the National Taiwan University Hospital. He is a staff member in the Department of Oncology at the University Hospital since 1995. Dr Yang received his MD from National Taiwan University (NTU) in 1986 and completed his internal medicine residency at the NTU Hospital. Between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU.

Dr Yang's research focuses on lung cancer treatment and the mechanism of multidrug resistance of chemotherapy or targeted therapy. His basic research works included molecular mechanisms of resistance and reversal of resistance to chemotherapeutic agents and tyrosine kinase inhibitors. Dr. Yang is a leader in lung cancer clinical studies, especially in the development of epidermal growth factor receptor tyrosine kinase inhibitors. He and other Asian investigators have established EGFR TKI as the front line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the global principle investigator (Lux Lung 1,2,3) of several pivotal studies that led to the global approval of 2nd generation irreversible EGFR TKI, afatinib. His active research now focus on development of 3rd generation EGFR TKI and contributed to the approval of osimertinib. His current research focused on targeted and targeted therapy and immunotherapy combination approach for lung cancer patients. He published more than 150 papers in peer reviewed journals. He served in the editorial board of Annals of Oncology, Lung Cancer and is the current associate editor of Journal of Thoracic Oncology and Nature Scientific Report. He received 2nd Kobayashi Foundation Cancer Research Award in Asian Clinical Oncology Society in 2012 and distinguished research award of National Science Council, Taiwan in 2012-2015 and distinguished research award of Ministry of Science and Technology, Taiwan from 2016-2018. He is the recipient of TECO award for biotechnology in 2015.

COURSE OFFICERS

Ji-Youn Han
Goyang-si, South Korea

Ji-Youn Han is Head of the Center for Lung Cancer and of the Division of Precision Medicine and Cancer Informatics at the Research Institute and Hospital of the National Cancer Center in Goyang-si, Korea.

Dr Han graduated in 1989 from the College of Medicine, the Catholic University of Korea, Seoul, Korea, and obtained her MS and PhD degrees in internal medicine in 1995 and 1998, respectively. In 2003-2004, she was Visiting Assisting Professor in the Department of Thoracic/Head and Neck Medical Oncology of the University of Texas MD Anderson Cancer Center in Texas, USA.

Dr Han is actively involved in lung cancer clinical trials, and her work has been published over 100 times in journals including J Clin Oncol, *Cancer Research*, *Clinical Cancer Research*, and *J Thorac Oncol, etc.*

Yuichiro Ohe
Tokyo, Japan

Yuichiro Ohe, MD, PhD is a Deputy Director and Director of Thoracic Oncology Department of National Cancer Center Hospital (NCCH) in Tokyo, Japan. He is President of Japanese Society of Medical Oncology (JSMO), a Board of director of International Association for the Study of Lung Cancer (IASLC) and Chair of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. He graduated The Jikei University School of Medicine in 1984 and got M.D. degree and also received Ph.D. degree in 1991. He has been working in NCCH in Tokyo and National Cancer Center Hospital East in Kashiwa since 1989. He was also working in University of Miami School of Medicine in 1992 and 1993 as a Postdoctoral Research Associate. His research field is development of new treatments for lung cancer including chemotherapy, multidisciplinary treatment, immunotherapy and translational research. He has been conducting and participating many clinical studies such as JCOG studies, pharmaceutical company oriented studies and global studies for lung cancer. He has more than 250 published papers in this field.

COURSE OFFICERS

Ross Soo
Singapore

Ross Soo is a Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore, and an Adjunct Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore.

He received his medical degree from Monash University, underwent specialist training in Melbourne and Sydney and subsequently became a Fellow of the Royal Australasian College of Physicians and the Academy of Medicine, Singapore. He specializes in lung cancer, head and neck cancer and leads the Lung tumor Group at the National University Cancer Institute, Singapore.

His professional affiliations include memberships of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the Singapore Society of Oncology. He sits on various committees including Ministry of Health Drug Advisory Committee (DAC), Medical Oncology Specialist Training Committee, Chapter of Medical Oncology Executive Committee, and he is the Chair of the Communications Committee (IASLC), Chair of the National Healthcare Group Domain-Specific Ethics Review Board and co-chair for the DAC-Oncology Drug Subcommittee.

His research interests are in lung cancer and nasopharyngeal cancer and he has published more than 100 papers in journals including *Cell*, *Nature Medicine*, *Nature Communications*, *Science Translational Medicine*, *JCI Insight*, *Journal of Clinical Oncology*, *Lancet Oncology*, *Annals of Oncology*, *Cancer Research* and *Clinical Cancer Research*.

Chao-Hua Chiu
Taipei, Taiwan

Dr. Chao-Hua Chiu is currently the Associate Professor at the School of Medicine, National Yang-Ming University and the Chief at the Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital. He is now also the Secretary General of Taiwan Society of Clinical Cytology. He received his MD degree at Taipei Medical University and his specialty training in both Pulmonology and Medical Oncology at Taipei Veterans General Hospital. Dr. Chiu was a visiting scientist at the Department of Molecular and Cellular Oncology, MD Anderson Cancer Center during 2006-2008. His main clinical and research interests include the diagnosis and management of lung cancer, mesothelioma and thymic malignancies.

COURSE OFFICERS

Dae Hee Han
Seoul, South Korea

Dr. Dae Hee Han graduated from Seoul National University School of medicine in 1993, and received his intern and radiology resident training at Seoul National University hospital. Previously, he worked at several different academic institutions, including a one-year visit to Stanford Medical center. Currently he is working for Seoul St. Mary's hospital as a professor of Radiology department. His research is focused on thoracic radiology and thoracic intervention, and the results were published at many international journals, including Radiology, Chest, and AJR.

Tony Lim Kiat Hon
Singapore

Associate Professor Tony Lim leads the Department of Anatomical Pathology in Singapore General Hospital. His research interests include molecular genetics, personalised medicine and the study of lung, liver and gastrointestinal diseases.

As the Head of Section of Translational Pathology Centre and the Clinical Director of Personalised OMIC Lattice for Advanced Research and Improving Stratification (POLARIS@SingHealth), A/Prof Lim collaborates with many industry and non-industry partners, contributing his clinical expertise to numerous research projects leading to new developments and findings published in many peer-reviewed journals.

A/Prof Lim is currently the Academic Vice-chair (Strategic Programmes) in the Pathology Academic Clinical Programme, and directs many research initiatives which are instrumental in translating discovery into diagnostics.

In addition to research, he has a passion in teaching, and is an Adjunct Associate Professor in both Duke-NUS Medical School and Nanyang Technological University. A/Prof Lim is also a Clinical Core Faculty Member in the SingHealth Pathology Residency Programme.

COURSE OFFICERS

Se-Hoon Lee
Seoul, South Korea

Se-Hoon Lee has been a faculty member at Samsung Medical Center, Seoul, South Korea since 2015 and worked as a faculty at Seoul National University Hospital, Seoul, South Korea between 2005 and 2015. He was trained as a resident doctor and clinical fellow at Seoul National University Hospital, Seoul, South Korea.

Dr. Lee is now a professor and medical oncologist, specialized in management of lung cancer, head and neck cancer and brain tumor. He has conducted and participated in clinical trials of these cancers. He has lead and participated in precision medicine trials (molecular screening, umbrella and basket ones) and early clinical trials including the first-in-human ones.

Dr. Lee is also a translational researcher focusing on cancer genomics and immunogenomics. He is author of more than two-hundred publications dealing with clinical and translational cancer field. He worked as a visiting scholar at Dana-Farber Cancer Institute and Broad Institute in Boston, USA for one and a half year since July, 2009. His research work was supervised by Dr. Matthew Meyerson, one of the leaders of The Cancer Genome Atlas.